Caplin Point Laboratories rises as its arm gets USFDA`s final approval for Norepinephrine Bitartrate Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Caplin Point Laboratories is currently trading at Rs. 1025.85, up by 2.25 points or 0.22% from its previous closing of Rs. 1023.60 on the BSE.
The scrip opened at Rs. 1026.00 and has touched a high and low of Rs. 1033.95 and Rs. 1011.65 respectively. So far 3355 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1122.00 on 06-Sep-2023 and a 52 week low of Rs. 575.00 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1056.90 and Rs. 1010.10 respectively. The current market cap of the company is Rs. 7761.04 crore.
The promoters holding in the company stood at 70.63%, while Institutions and Non-Institutions held 2.95% and 26.42% respectively.
Caplin Point Laboratories’ subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) Single-Dose Vial, a generic therapeutic equivalent version of (RLD), LEVOPHED injection of Hospira Inc.
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients with acute hypotensive states. According to IQVIA (IMS Health), Norepinephrine Bitartrate Injection USP had US sales of approximately $40 million for the 12-month period ending June 2023.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
